CASI Pharmaceuticals, Inc.
23
1
1
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 23 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
5%
1 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Role: lead
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Role: lead
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
Role: lead
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Role: collaborator
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
Role: lead
Study of ENMD-2076 in Patients With Multiple Myeloma
Role: lead
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Role: lead
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
Role: lead
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
Role: lead
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
Role: lead
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
Role: lead
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
Role: lead
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
Role: lead
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Role: lead
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
Role: lead
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
Role: lead
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Role: lead
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
Role: lead
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
Role: lead
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
Role: lead